Bluechiip Ltd - Proactiveinvestors UK · 2018-12-08 · Other addressable markets Strategy Adjacent Markets Cold Chain Logistic Pharmaceuticals Cold Chain Logistics Food Industrial

© Bluechiip Ltd | All Rights Reserved


Unique patented MEMS technology combining secure wireless tracking with integrated temperature sensing for extreme environments

Bluechiip LtdMar 2017

© Bluechiip Ltd | All Rights Reserved 2

DisclaimerMaterial used in this presentation is a summary of available information, and while given in good faith, isprofessional opinion only. Any investor in Bluechiip Limited (BCT) should refer to all BCT ASX releases andstatutory reports before considering investment in the company.

Certain information may have been derived from third parties and though BCT has no reason to believe thatit is not accurate, reliable or complete, it has not been independently audited or verified by BCT.

Any forward-looking statements in this presentation involve subjective judgment and analysis and are subjectto uncertainties, risks and contingencies, many of which are outside control of, and maybe unknown to, BCT.Neither BCT, nor its officers, employees and advisors make or give any representation, warranty or guaranteein relation to this presentation.

BCT reserves right to update, amend or supplement information in this presentation at any time in itsabsolute discretion without incurring any obligation to do so.

Bluechiip Sample TrackingIntroduction


Our Team

Introduction

Board

Corporate

Iain Kirkwood Andrew McLellan Michael Ohanessian

Chairman

Experienced investor and non-executive director (listed and unlisted). Iain has considerable practical and operational experience gained from a successful financial career spanning 35 years including in resources, manufacturing and latterly healthcare in Australia, Britain and the USA. Iain has been a major shareholder in Bluechiip for over 5 years.

Managing Director

Experienced in innovation and commercialisation combined with significant technical and operational background. Andrew has held senior positions including as VP of Business Development in North America and Director at Leica Microsystems (previously Vision BioSystems a division of the publicly listed Vision Systems), and as CEO of the Advanced Manufacturing Co-operative Research Centre (AMCRC)

Non-executive Director

CEO and Managing Director of Praemium Ltd, Michael brings executive experience in technology-related businesses. Previously CEO of Vision BioSystems Michael led the technology commercialisation into global markets before its parent Vision Systems was acquired by US based Danaher Corp. Michael brings a mixture of operational, strategic and leadership capabilities to his role at Bluechiip.

Team

Scott Turner Dr Ian Johnston Irvin Teoh David White & Hugh Douglas

Engineering Manager

Product Engineering Manager, MEMS (EU)

Finance Manager Business Development North America (US)

Oscar Val

Technical Sales and Marketing Manager

4

Corporate overview

CorporateIntroduction


Top Shareholders

Summary (As at 31 Jan 2017)

Share Price

Pulitano Family 8.82%

Dr. Stephen Woodford 8.37%

Chairman & Entities 7.32%

Planet Innovation 5.02%

Top 20 Shareholders 51.48%

Founder 1.57%

Number of Shareholders 708 Shares on Issue 271,810,092

Share Price 4.0c Market Cap. $10.87m

Cash Balance (31 Dec 2016) $1.092m

0

2

4

6

8

10

12

14

16

0c

1c

2c

3c

4c

5c

6c

7c

8c

Vo

lum

e (

mill

ion

)

Shar

e P

rice

(ce

nt)

BluechiipSample tracking for extreme environments using MEMS sensors

• Unique Micro-Electro Mechanical Systems (MEMS) micro

device, superior to labels, barcodes and RFID

• Provides ID extremely difficult to copy

• Operates reliably between -196ᵒC & 100ᵒC

• Instant sample temperature sensing

• Reads in under 0.3 second, even through frost

• Sterilisation resistant including Gamma radiation

• Can be moulded into any plastic

• Reduces human error

• Increases productivity


Our Product : Chip + Reader + Software

OverviewIntroduction

6© Bluechiip Ltd | All Rights Reserved

Alternative technologies

Our SolutionBiobanking Today

Gamma Resistant

Cryo safeSurvives extreme temps

Non visual IDReads through frost

On-board sensorTemperature sensing

Reduced human error

Productivity improvements

HUMAN READABLE BARCODES RFID BLUECHIIP


Primary Applications

7

• Sample tracking and identification• Biopreservation• Life sciences• Research • Pharmaceuticals• Personalised Therapies


Primary Market Opportunity

MarketStrategy

Cryogenic(-196C°)

Non-cryogenic (-80C°)

Total biobanking: 2B samples in storage300M new samples per year

Sources: Visual Fuse and MarketsandMarkets 2014

Global Biopreservation Market Greater than $2B in 2015


SegmentsBiobanking Today

IVF Sperm/EggsBloodTissue StemCellBiologics

Biosample tracking technology is not keeping up with the increasing value of biosamples


Biopreservation Trends300+ million biosamples per annum, 2+ billion in storage

NeedsBiobanking Today

High volume processing

Dual labelling

Criticality of temperature on quality

Increasing demand for Cryogenic storage

Icon here

Icon here

Icon here

Icon here

Other addressable markets

Adjacent MarketsStrategy

Cold Chain LogisticPharmaceuticals

Cold Chain Logistics Food

Industrial and Manufacturing

Security & Defence

Icon here

Icon here

Icon here

Icon here

Item level temperature tracking of pharmaceuticals through-out the cold chain cycle.

Item level temperature tracking of frozen and temperature sensitive food stuffs through-out the cold chain cycle.

High temperature tracking, structural health monitoring, tracking of tools and parts that are exposed to ionizing radiation or gamma radiation including sterilised medical devices, disposables and some food products.

Anti counterfeiting fashion, food and high value commercial items. Cloning a bluechiip® tag is extremely difficult. tracking of tools and parts that are exposed to ionizing radiation, security and defense.



Strategic Progress and Sales Pipeline

12


Solutions for OEM Partners

ProductsTechnology Introduction

High Value Target Markets

Strategy


1,800,000

2,500,000

3,000,000

3,700,000

15,000,000

7,500,000

IVF PROTEINCRYSTALLOGRAPHY

REGENERATIVEMEDICINE OTHERCRYOANDTRANSPORT

GENERALBIOBANKING GENERALBIOBANKING-NEXTGENERATIONCHIPS

NUMBER

OFUNITS

Annualconsumables(Chiips) Storedconsumables

Bluechiip Opportunity(USD) $20m+ $2.5M+ $30M+ $30M+ $200M+

OEM PIPELINE CLIENTS

Agreement Dec 2015Revenue Mar 2016Displayed July ‘16Target Launch 2017

Executed agreement Evaluation in progressValidation Customers

Executed agreement Evaluation in progressValidation customers

Evaluation agreements & developer kits in progress

Developer kits sold with multiple vendors & validation customers

R&D Development.High value over temperature sensors

30

0 M

2 B

30

0 M

$1.5B+

33

M

Bluechiipopportunity ($US)

Market Opportunities

• Partner pipeline grown to over 30 opportunities

• Genea Biomedx – OEM Supply Agreement Executed

• Planet Innovation - OEM Supply Agreement and Investment

• 2016: 9 Developer & Starter Kits sold with sales accelerating

• Mar : Autism CRC – End user. Ongoing consumables• Jun: US Cryogenics consumables manufacturer

• Australian researcher organisation• Aug: Centre for Disease Control China (CDC China)• Sep: US Auto ID and Data Capture Company• Nov: Kit sale to CDC China

• 2 Kit sales to SIAD in EU –biobank solution provider• Kit sale to Denmark University – OEM validator

• Dec: Kit sale to The Netherlands

2016 Pipeline and ResultsDramatic increase

Pipeline ProgressStrategy


Engagement (Non-Disclosure

Agreement)

Sale of developer/trial kit,

evaluation agreement

Development & Supply agreement

Demonstration in market

Commercial product

“Bluechiip Inside”

OEM

End User

Validation Validation


Genea Biomedx License & Supply Agreement

PartneringStrategy

• Dec 2015 Genea Biomedx – OEM Supply Agreement Executed

• Incorporate Bluechiips technology to Genea’s range of Assisted

Reproductive Technologies instruments

• Feb 2016 Successfully Completed concept due diligence

• July 2016 Demonstration in Market at (ESHRE) trade show Europe

• 2017 Pilot & Launch Commercial Product


Bluechiip IVF Transport CoolerActive ID and Temperature Recording in Liquid Nitrogen -196o C

PartneringStrategy

https://www.youtube.com/watch?v=8BbZZgXnKjY

https://www.youtube.com/watch?v=8BbZZgXnKjY

18

Planet Innovation OEM Partnership


PartneringStrategy

• OEM Supply and Master Services Agreement Executed in September ‘16

• Planet Innovation direct investment with a significant shareholding

• Actively pursuing partnerships to incorporate Bluechiip technology into Planet Innovation’s Partners Products


Product PipelineChiips

ProductsStrategy

Market feedback. Independent SurveySample Storage Quality & Identification Tracking Trends 2016

Market feedbackStrategy


• Largest markets US (47%) and Europe (27%)

• Freeze/Thaw cycles regarded as the main obstacle to sample quality

• Stored samples exposed to at least 1 significant temperature change per day

• Overtemperature regarded as the most valuable feature of all

• Estimated cost to replace a poor quality sample is USD 51-100. With some samples

well in excess of thousands of dollars.

• For MEMS ID fitted 2ml vials market potential is around USD $40M a year (2ml vials account for only a portion of the total vial storage market)

Source: Independent market research report, Nov 2016, HTStec


Product PipelineReaders

ProductsStrategy

Bluechiips• Government co-funded projects with Melbourne and Swinburne

Universities to adapt to multiple formats

• Overtemperature chip, 2nd stage funding awarded & Patent Application submitted

Over

T°C


Bluechiip Blue TrayActive ID and Temperature Recording in Transit

ProductsStrategy

https://www.youtube.com/watch?v=8H350vEC9GQ

https://www.youtube.com/watch?v=8H350vEC9GQ

1. Well protected and expanding differentiated IP portfolio

2. Large growing target market with very large adjacent market opportunities

3. Dramatically increasing partner pipeline with well advanced product development

4. Partner opportunity conversion with 2 executed licence and supply agreements

5. Initial repeat revenues with licence, service and product sales expected to grow in 2017

on partner’s product launch

Summary

Pipeline ProgressStrategy


Need hi-res image

Contact



Andrew McLellan, Managing Director & CEOTel: +61 (0)3 9763 9763Mob: +61 (0)457 823 470Email: [email protected]

mailto:[email protected]

http://www.bluechiip.com/

Bluechiip Ltd - Proactiveinvestors UK · 2018-12-08 · Other addressable markets Strategy Adjacent Markets Cold Chain Logistic Pharmaceuticals Cold Chain Logistics Food Industrial

Documents